SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following positive earnings and news of a significant AI lease deal, with the community buzzing about a potential short squeeze. A price target increase from Roth Capital is adding fuel to the fire, as investors discuss the company's prospects in AI infrastructure and data centers. Some community members are comparing it to other high-growth stocks and discussing strategies around calls and puts, while others are considering it for long-term investment.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp is trending due to a strategic partnership focused on developing quantum-resistant chips for U.S. defense applications, igniting discussions about future government contracts. The community is actively evaluating the company's growth potential relative to other quantum computing stocks. Many investors are describing LAES as undervalued with potential for a significant upward trajectory.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors discuss the potential for a short squeeze, fueled by high short interest and recent positive developments, including a partnership with Google. Community members are closely monitoring resistance levels and anticipating a breakout, drawing comparisons to other AI and high-performance computing data center plays. The focus remains on the company's transition towards AI infrastructure and its potential for growth in the sector.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to a recently announced $2 billion equity offering, leading to community debate about dilution and valuation. While some view the offering, priced at a premium, as a bullish sign of investor confidence in the quantum computing company's future, others express concerns about the long-term impact on shareholders and the sector's high valuations.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Quoin Pharmaceuticals Ltd - ADR

Quoin Pharmaceuticals is trending following news of positive clinical data for their QRX003 treatment, specifically in a pediatric peeling skin syndrome study. The community is actively discussing the stock's low float and potential for a short squeeze, drawing comparisons to other recent low-float biotech runners. Some traders caution about dilution and the company's history, while others remain bullish, citing the potential of the treatment and market opportunity.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARA is trending as discussions revolve around its potential to catch up with other miners like CLSK and IREN, with some expressing frustration over its underperformance and management. Community members are debating whether its current valuation reflects its Bitcoin holdings and future AI prospects. Short interest remains high, fueling speculation about a potential squeeze.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is surging, fueled by speculation around a potential ETF and positive technical indicators, leading to renewed interest in the crypto asset. The community is actively discussing price targets and potential breakouts, while also debating whether this rally will be sustained. Some traders are pointing to Litecoin's historical performance relative to Bitcoin, suggesting it is undervalued.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company ($ABAT) is trending as the stock price increases, spurring excitement among long-term investors who have been holding shares for several years and are now seeing significant gains. Community members are actively discussing potential price targets and the impact of upcoming news, particularly around the PFS (Pre-Feasibility Study). The company's positioning in lithium recycling, especially with potential government support and China's export controls, is also a key talking point.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending as investors react to recent news, including a new multi-launch agreement with Japan's iQPS. The community is actively discussing the potential impact of this deal, along with speculation about upcoming catalysts like the Neutron launch and potential government contracts. Some traders caution about short-term overvaluation, while long-term bulls remain confident in the company's growth prospects.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as traders debate whether its recent surge is justified by fundamentals or fueled by a short squeeze, with community members highlighting both bullish and bearish arguments.  The launch of a new 2x short ETF (RGTZ) has added another layer to the discussion, as some believe it will exacerbate the squeeze while others see it as a sign of an impending reversal.  Quantum computing stocks are also in focus, and the community is comparing RGTI's valuation and potential against competitors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail investors on Stocktwits are optimistic about Genius Group’s pivot and hope to see the same returns as MicroStrategy after the latter pivoted to a Bitcoin-first strategy in 2020. | Source: Pixabay

Why Is Genius Group Stock Rising Today?

Genius Group repurchased its stock on the open market at an average price of $0.90 per share from August 28 to September 11, 2025.

Equity

Global Equity ETFs Draw Rising Investor Interest

Global equity funds saw $10.65B inflows as Fed rate cut bets, a weak dollar and diversification needs drive investors abroad.

U.S.-listed shares of Birkenstock Holding were up 3% in premarket trading on Thursday, ahead of the German footwear company's quarterly report before the market opens.Analysts expect its third-quarter revenue to rise 19.3%, similar to the preceding two quarters, according to Kofin data. Investors&nbsp;will be watching for comments on the impact of tariffs, price hikes, supply chain disruptions, and the demand landscape in North America and Europe.Piper Sandler, which reaffirmed its 'Overweight' rating this week, noted that unfavorable foreign exchange rates could pressure the company's reported revenue.Birkenstock, known for its clogs or sandals, is in a notably good position. In May, the company raised its annual profit outlook and authorized a $200 million share buyback. Still,&nbsp;<a href="https://stocktwits.com/symbol/BIRK">BIRK shares</a> are down 11% year-to-date.The stock has gained nearly 6% in the last two sessions, and the latest retail sentiment reading on Stocktwits is ‘extremely bullish,’ signaling investor optimism.<figure class="image"><img style="aspect-ratio:629/72;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_14_at_2_38_43_PM_png_0145047a9b.webp" alt="Screenshot 2025-08-14 at 2.38.43 PM.png" width="629" height="72"><figcaption>BIRK sentiment and message volume as of August 14 | Source: Stocktwits</figcaption></figure>Late last month, Goldman Sachs&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-scores-buy-rating-from-goldman-sachs-shares-rise/choGriXR5vX">raised</a> its rating on Birkenstock to ‘Buy’ from ‘Neutral,’ citing "robust" momentum and an attractive valuation for the company's shares in a challenging&nbsp;macroeconomic backdrop.Footwear companies face broad pressure from U.S. import tariffs on major Asian manufacturing hubs, including China and Vietnam.Swiss company On Holding posted strong quarterly sales and raised its full-year target,&nbsp;attributing the increase to recent price increases on its shoes. In the future, CEO Martin Hoffmann&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/on-holding-ceo-martin-hoffmann-says-the-sportswear-maker-is-in-a-good-position-to-digest-tariffs/chrCS0bRd9p">told</a> Stocktwits that the company is now "in a very good position to digest" the tariffs.Birkenstock also raised prices in the U.S. last month.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Various Birkenstock shoes are displayed on shelves in a Birkenstock store on Ehrenstraße. Photo: Rolf Vennenbernd/dpa (Photo by Rolf Vennenbernd/picture alliance via Getty Images)

Why Are Birkenstock Shares Rising Premarket?

The move shows optimism ahead of the German footwear company's quarterly report.

Birkenstock Holding (BIRK) shares rose over 1.5% in Thursday's session and another 2% in extended trading, after Goldman Sachs raised its rating on the sandal maker.The research firm raised the rating on the company's shares to 'Buy' from 'Neutral,' while maintaining its $60 price target, according to a summary of the investor note on The Fly. That indicates an over 15% upside to BIRK's last closing price.Currently, 20 of the 22 analysts covering the stock have a 'Buy' or higher rating, and two rate it 'Hold,' according to Koyfin data. Their average price target is $72.26.Goldman Sachs sees "robust" momentum and an attractive valuation for Birkenstock in a challenging macro backdrop. The company has a "strong" product proposition, with pricing power and opportunities to win share in a "highly fragmented" footwear market, the research firm said.Goldman Sachs also noted Birkenstock's vertically integrated manufacturing setup in Europe, which would support the company's margins.Although&nbsp;<a href="https://stocktwits.com/symbol/BIRK">BIRK shares</a> have rebounded over the last couple of weeks, they remain 15.5% below their 2025 peak achieved on Jan. 30.On Stocktwits, retail sentiment shifted to 'neutral' early Friday from 'bearish' the previous day, with several users&nbsp;taking note of the latest upgrade.<figure class="image"><img style="aspect-ratio:1416/154;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_25_at_10_41_26_AM_png_d52d1b15f5.webp" alt="Screenshot 2025-07-25 at 10.41.26 AM.png" width="1416" height="154"><figcaption>BIRK sentiment and message volume as of July 25 | Source: Stocktwits</figcaption></figure>In May, Birkenstock raised its annual profit outlook and authorized a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-authorizes-200m-buyback-but-retail-remains-cold/ch0AkaLRbti">$200 million share buyback</a>.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/chinese-e-commerce-giant-jd-com-could-reportedly-snap-up-media-markt-parent-for-2-6-b-retail-bulls-eye-breakout/choGqh1R5v9">Chinese E-Commerce Giant JD.com Could Reportedly Snap Up MediaMarkt Parent For $2.6B: Retail Bulls Eye Breakout</a>

A Birkenstock shoe displayed on in a Birkenstock store in North Rhine-Westphalia, Cologne, Germany. (Photo by Rolf Vennenbernd/picture alliance via Getty Images)

Birkenstock Scores 'Buy' Rating From Goldman Sachs, Shares Rise 

The sandal maker has "robust" momentum, attractive valuation, and pricing power, the research firm says.

German sandal&nbsp;maker Birkenstock has filed an infringement lawsuit in India's capital, New Delhi, against four footwear traders, four factories, and two unnamed individuals following a company investigation revealed the production, sale, and export of counterfeit products, according to a Reuters report.The&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/sustainability/boards-policy-regulation/birkenstock-cracks-down-fakes-india-court-ordered-factory-visits-held-sources-2025-07-06/">report</a>, which cites people familiar with the matter,&nbsp;comes as the footwear industry is garnering increased attention in India. Earlier this month, Crocs (CROX) secured a court nod to pursue a nine-year-old infringement case. At the same time,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/prada-credits-centuries-old-indian-kolhapuri-craftsmanship-behind-open-toe-sandals-design-unveiled-at-milan-show/chmZe7GRReZ">Prada drew criticism</a> after its sandals at a Milan showcase looked nearly identical to Indian Khandasari chappals, prompting the Italian fashion brand to acknowledge the similarity.According to the report, Birkenstock filed the lawsuit in the Delhi High Court in May. It claims that Birkenstock counterfeits were being manufactured in rural areas near the North Indian tourist hub of Agra and sold both locally and exported to other countries. The court has ordered law enforcement inspections of these facilities.India is a key market for the German brand, which last month opened its 50th standalone store in the country,&nbsp;in the financial capital of Mumbai.On Stocktwits, the retail sentiment for BIRK remained 'bullish,' unchanged from a week ago.&nbsp;<a href="https://stocktwits.com/symbol/BIRK">Birkenstock shares</a> are down nearly 14% year-to-date.<figure class="image"><img style="aspect-ratio:615/69;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_2_06_14_PM_png_bdebef4034.webp" alt="Screenshot 2025-07-07 at 2.06.14 PM.png" width="615" height="69"><figcaption>BIRK sentiment and message volume as of July 7 | Source: Stocktwits</figcaption></figure>The development comes at a time of strength for the company. It recently reported strong results for its fiscal second quarter,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-raises-annual-profit-forecast-shares-retail-sentiment-surge/chivoCURbnc">raised its annual profit forecast</a>, and authorized a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-authorizes-200m-buyback-but-retail-remains-cold/ch0AkaLRbti">$200 million buyback</a>.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Birkenstock Reportedly Sues Indian Footwear Makers Over Counterfeits Amid Rising Industry Scrutiny

India is a key market for the German brand, which last month opened its 50th standalone store in the country.

Nasdaq-listed shares of argenx SE (ARGX) rose 2% by Friday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://argenx.com/news/2024/argenx-announces-european-commission-approval-of-vyvgart--efgart">announced</a> that the European Commission approved its VYVGART 1,000 mg subcutaneous (SC) injection in the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP).CIDP is a rare and often progressive autoimmune disease of the peripheral nervous system. Patients with CIPD experience a range of mobility and sensory issues, including trouble standing from a seated position, pain and fatigue, and frequent tripping or falling.The European Commission approved the subcutaneous injection as a monotherapy for patients with the disease who have received prior treatment with corticosteroids or immunoglobulins.The EC approval will apply to all 27 European Union Member States, as well as to Iceland, Liechtenstein, and Norway.VYVGART for SC injection is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional. The company stated that it is “working closely” with local regulatory authorities to ensure patients can access the treatment as soon as possible.The approval is based on a clinical trial that demonstrated 66.5% of patients treated with VYVGART SC showed evidence of clinical improvement, including improvements in mobility, function, and strength. The study also revealed a 61% reduction in the risk of relapse compared to the placebo.This regulatory approval marks the second for VYVGART SC in Europe, which first received approval as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.On Stocktwits, retail sentiment around argenx remained within ‘bullish’ territory over the past 24 hours while message volume remained ‘normal’.<figure class="image"><img style="aspect-ratio:631/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_20_at_2_09_51_PM_png_2b09c4d552.webp" alt="ARGX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on June 20, 2025 | Source: Stocktwits" width="631" height="68"><figcaption>ARGX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on June 20, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/ARGX">ARGX stock</a> is down by 12% this year but has gained over 40% in the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-considered-perplexity-acquisition-before-14-3-b-scale-ai-deal/chlxqohRRPz">Meta Reportedly Considered Perplexity Acquisition Before $14.3B Scale AI Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an argenx SE logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Argenx Gets European Commission Approval For Drug To Treat Rare Autoimmune Disease, But Stock Fails To Garner Retail Attention

VYVGART for SC injection is available in vials or prefilled syringes and can be administered by a patient, caregiver, or healthcare professional.

U.K.-based biopharmaceutical company GSK plc (GSK) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gsk.com/en-gb/media/press-releases/gsk-s-rsv-vaccine-arexvy-accepted-for-regulatory-review-by-the-european-medicines-agency-to-expand-use-in-adults-18-years-and-older/">said</a> on Friday that the European Medicines Agency (EMA) has accepted its regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to include adults aged 18 years or above.Arexvy is already approved in the European Economic Area for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk for RSV disease due to underlying medical conditions.RSV is a common contagious virus affecting the lungs and breathing passages and impacts an estimated 64 million people of all ages globally every year, GSK said. The virus can aggravate conditions such as asthma and chronic heart failure, leading to hospitalisation and death.The company is looking forward to a decision from the regulator on the application in the first half of 2026.Meanwhile, the firm is continuing to seek an expansion for the treatment scope of its RSV vaccine in geographies including the U.S. and Japan.Arexvy brought in 78 million British pounds ($106.08 million) for GSK in the first quarter of 2025, down 57% from the corresponding period of 2024, following a drop in sales in the U.S., and accounting for just 1% of its overall turnover in the period.On Stocktwits, retail sentiment around GSK remained unmoved within ‘extremely bearish’ territory over the past 24 hours while message volume remained unchanged at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1258/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_12_12_04_PM_png_f36e4b25b0.webp" alt="GSK's Sentiment Meter and Message Volume as of 12:15 p.m. ET on Jun 13, 2025 | Source: Stocktwits" width="1258" height="126"><figcaption>GSK's Sentiment Meter and Message Volume as of 12:15 p.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure>NYSE-listed shares of GSK are down by 3% as of Friday noon. <a href="https://stocktwits.com/symbol/GSK">The stock</a> is up approximately 22% this year and has increased by about 1% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/urogen-price-target-upgrade-after-fda-approval-for-cancer-medicine/chli4GKRRbJ">UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK’s Application To European Authorities For Expanded Use Of RSV Vaccine In Younger Adults Fails To Rejuvenate Retail Optimism

The company is looking forward to a decision from the regulator on the application in the first half of 2026.

Brookfield Asset Management (BAM) has announced a potential investment of up to SEK 95 billion (approximately $10 billion) to develop AI infrastructure in Sweden, marking one of its largest AI initiatives in Europe to date.The funding will be directed toward developing a large-scale AI center in Strängnäs, forming a key component of Sweden’s digital infrastructure aligned with its national AI goals.&nbsp;The facility is expected to grow its capacity from 300 megawatts (MW) to 750 MW, supported by a land deal encompassing around 350,000 square meters.Brookfield expects the Strängnäs facility to create over 1,000 permanent positions, with another 2,000 jobs expected during the 10- to 15-year construction phase.&nbsp;“To compete in the development of AI and realize its economic productivity, it is important to invest at scale in the infrastructure underpinning this technology,” said&nbsp;Head of Europe, Brookfield, Sikander Rashid.According to a Reuters report, the growing adoption of AI and regulations mandating data storage within Europe have sparked a surge in data center development across the region.&nbsp;Companies like Microsoft Inc. (MSFT), Meta Platforms Inc.(META), and Alphabet Inc. (GOOG, GOOGL) have selected Sweden for their facilities, drawn by the country's dependable power supply, infrastructure, and strong connectivity.&nbsp;Brookfield’s AI infrastructure includes more than €100 billion ($114 billion) allocated to areas such as digital connectivity, clean energy, and semiconductor ventures worldwide.&nbsp;In early 2024, the company introduced a €20 billion investment program in France, which features a €10 billion commitment to the country’s inaugural AI manufacturing facility.&nbsp;&nbsp;&nbsp;The New York-based global alternative asset manager oversees over $1 trillion in assets, focusing on long-term investments in real assets and essential service sectors.On Stocktwits, retail sentiment around Brookfield remained in ‘bearish’ territory.<figure class="image"><img style="aspect-ratio:644/74;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_04_083036_png_932e692b08.webp" alt="BAM's Sentiment Meter and Message Volume as of 08:30 a.m. ET on June 4, 2025 | Source: Stocktwits" width="644" height="74"><figcaption>BAM's Sentiment Meter and Message Volume as of 08:30 a.m. ET on June 4, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/BAM">Brookfield</a> stock has gained over 4% year-to-date and over 44% in the last 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/crowdstrike-stock-slumps-post-q1-print-as-analysts-turn-cautious/chkuff6RbwY">CrowdStrike Stock Slumps Post Q1 Print As Analysts Turn Cautious: Retail Seizes Pullback Opportunity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Exchange Rate: 1SEK = 0.10 USD1EUR = 1.14 USD

In this photo illustration, the logo of Brookfield Corporation is displayed on a smartphone screen on April 26, 2025, in Chongqing, China.

Brookfield Commits $10B To Sweden’s AI Expansion: Retail Sees No Reason To Cheer

The AI center in Strängnäs, Sweden, will expand capacity to 750 MW and create 3,000 jobs in the coming years.

German sandals&nbsp;maker Birkenstock Holding (BIRK)&nbsp;said on Wednesday that it plans to buy back $200 million worth of company shares and&nbsp;announced the sale of a block of shares by one of its investors.BK LC Lux MidCo, an entity affiliated with private equity firm L Catterton, is selling 15.7 million shares of Birkenstock at $52.50 a piece. That totals to over $824 million.The shares are being offered to public investors through underwriters in a secondary public offering.Meanwhile, Birkenstock has authorized a $200 million buyback&nbsp;by purchasing an estimated 3.7 million shares. The company's repurchase depends on the progress of the sale by BK LC Lux.Goldman Sachs and JPMorgan are acting as joint book-running managers for the offering.The move comes at a time of strength for the German shoe brand. Earlier this month, Birkenstock reported strong results for the last quarter and raised its annual profit forecast.Revenue rose by a higher-than-expected 19% for its fiscal second quarter, while net profit grew 68%.Birkenstock’s recent performance&nbsp;contrasts with that of other shoe brands, including Nike (NKE) and Crocs, which are grappling with uneven consumer demand following President Donald Trump’s tariff announcements last month.On Stocktwits, the retail sentiment was 'bearish,' unchanged from a month ago.<figure class="image"><img style="aspect-ratio:1276/146;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_29_at_2_30_55_PM_png_e313452594.webp" alt="Screenshot 2025-05-29 at 2.30.55 PM.png" width="1276" height="146"><figcaption>BIRK sentiment and message volume as of May 28 | Source: Stocktwits</figcaption></figure>Birkenstock was listed on the New York Stock Exchange in October 2023.Its shares are down 4.2%% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Birkenstock Authorizes $200M Buyback, But Retail Remains Cold

One of the company's investors is selling over $800 million worth of shares in a secondary market offering.

Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the company announcing positive data from one of its ongoing drug trials.Oncology company Merus on Thursday <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.merus.nl/news-releases/news-release-details/merus-petosemtamab-pembrolizumab-interim-data-demonstrates">said</a> that the combination of bispecific antibody Petosemtamab with Pembrolizumab demonstrated robust efficacy and durability in its ongoing phase 2 trial as of Feb. 27.Merus CEO Bill Lundberg said the data from the trial demonstrates that Petosemtamab in combination with Pembrolizumab can become “a new standard of care" in head and neck cancer and is “significantly better” than treatment with just Pembrolizumab.The company said that as of Feb. 27, 45 patients had been treated in the phase 2 trial, and the combination was generally well tolerated.The CEO also expressed optimism about sharing data from one or both of its late-stage combination trials in 2026.BofA on Friday hiked the price target on Merus to $92 from $70 while keeping a ‘Buy’ rating on the shares. The firm noted that the recently announced data set the combination as "the best-in-class treatment option for this patient population."The analyst’s new price target implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.BMO Capital also hiked the price target on Merus to $110 from $96 on Friday while keeping an ‘Outperform’ rating on the shares. BMO said it sees a 90% probability of the combination's approval for treating head and neck cancer.On Stocktwits, retail sentiment around Merus jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_23_at_10_48_55_AM_png_3d759215e6.webp" alt="MRUS's Sentiment Meter and Message Volume as of 10:50 a.m. ET on May 23, 2025 | Source: Stocktwits" width="626" height="63"><figcaption>MRUS's Sentiment Meter and Message Volume as of 10:50 a.m. ET on May 23, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/MRUS">MRUS stock</a> is up by about 30% this year and 25% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jp-morgan-bank-of-america-citigroup-wells-fargo-reportedly-explore-joint-stablecoin/ch0QZ5vRbqs">JPMorgan, Bank of America, Citigroup, Wells Fargo Reportedly Explore Joint Stablecoin</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled

BofA’s new price target of $92 implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.

SSgA Active Trust - SPDR Portfolio Developed World ex-US ETF

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

SPDW
SPDR Portfolio Developed World ex-US ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SPDW News

SPDWSPDR Portfolio Developed World ex-US ETF